LIMN 株価分析 — Liminatus Pharma, Inc. Class A Common Stock (Healthcare >> Biotechnology)
LIMN に関するよくある質問
LIMNのROE(自己資本利益率)は?
Liminatus Pharma, Inc. Class A Common StockのROEは8,383.35%です。
LIMNの配当利回りは?
Liminatus Pharma, Inc. Class A Common Stockの配当利回りは0.00%です。
LIMNの品質スコア(Quality Score)は?
当社のAIはLIMNの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
LIMNは今が買い時ですか?
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
LIMNはどのセクターに属しますか?
Liminatus Pharma, Inc. Class A Common StockはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
LIMN AI Analysis Summary
Our AI summary for LIMN: Liminatus Pharma, Inc. Class A Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 8,383.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.10
Price
-0.01
(-5.81%)
Day Change
|
|
|---|
LIMN, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROAが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.10 |
| PBV / Sector |
-53.18 / 5.21
|
| Earning Per Share | -0.16 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
5.41 M
GREAT
|
| Average 1W Daily Value |
0.79 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-07 08:11:57 |
| Symbol | LIMN |
| Name | LIMINATUS PHARMA, INC. CLASS A COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 67.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 7.05 / 9,672.56 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 12611 Hiddencreek Way, Cerritos, CA, United States, 90703
Phone: 213 273 5453
Website: https://liminatuspharma.com
Sector: Healthcare >> Biotechnology
Description: Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google